Vicore Pharma

• Sessions at the upcoming ERS include an oral presentation of additional Phase 2a AIR trial data of buloxibutid in IPF
• Additional presentations include preclinical and translational data reflecting the impact of buloxibutid’s upstream mechanism of action
• Vicore will additionally present on aspects of the Phase 2b ASPIRE trial designed to maximize patient attractiveness, ease of enrollment, and efficient study execution

Stockholm, August 29, 2024 – Vicore Pharma Holding AB (publ), unlocking the potential of a new class of drug candidates, angiotensin II type 2 receptor agonists (ATRAGs), today announced multiple presentations at the European Respiratory Society (ERS) Congress 2024, including an oral presentation and three poster presentations spanning preclinical and clinical data supporting the transformative potential of buloxibutid for patients suffering from idiopathic pulmonary fibrosis (IPF). The ERS Congress 2024 will be held September 7–11 in Vienna, Austria.

“We are pleased to showcase a series of presentations at the ERS Congress 2024,” said Ahmed Mousa, Chief Executive Officer of Vicore Pharma. “In addition to further Phase 2a AIR data, these presentations will highlight the power of our tissue repair mechanism to impact human IPF lung tissues and the precise cell types responsible for driving the fibrotic process in this disease. We also look forward to sharing more information on the patient-friendly design of our Phase 2b ASPIRE trial of buloxibutid in IPF to drive efficient enrollment.”

Vicore’s Presentations at ERS Congress 2024 Include:

Oral Presentation
Title: AIR – an open-label, 36-week, clinical trial of buloxibutid – investigating the disease modifying potential of a novel angiotensin II type 2 receptor agonist in IPF
Session: Novel management strategies in pulmonary fibrosis
Abstract: OA2859
Presentation Date and Time: Monday, September 9 at 11.00 CET

Poster Presentation
Title: Effects of the angiotensin II type 2 receptor agonist buloxibutid on human lung myofibroblasts and IPF lung tissue
Session: Novel insights in the pathogenesis of pulmonary fibrosis
Abstract: PA3380
Presentation Date and Time: Monday, September 9 at 12.30 – 14.00 CET

Poster Presentation
Title: Patients and caregivers’ core aspirations to maximize the attractiveness of ASPIRE - a phase 2b trial to investigate the disease modifying potential of buloxibutid in IPF
Session: Pulmonary fibrosis and all of its clinical aspects
Abstract: PA2443
Presentation Date and Time: Monday, September 9 at 8.00 – 9.30 CET

Poster Presentation
Title: COMPANION - a randomised controlled study to evaluate the impact of a digital therapy on anxiety and quality of life in patients with pulmonary fibrosis
Session: Advancing clinical trials and care in pulmonary fibrosis
Abstract: PA675
Presentation Date, Time and Location Sunday, September 8 at 8.00 – 9.30 CET

Posters will be available on Vicore’s website from September 9, 2024.

For further information, please contact:
Megan Richards, VP of IR, Communications, and Portfolio Strategy
+1 978 269-4372
megan.richards@vicorepharma.com

This information was submitted for publication on August 29, 2024, at 08:00 CET.

About Vicore Pharma Holding AB (a clinical-stage biopharmaceutical company)
Vicore is an innovative clinical-stage pharmaceutical company unlocking the potential of a new class of drugs with disease-modifying potential. The company is establishing a portfolio in respiratory and fibrotic diseases, including idiopathic pulmonary fibrosis (IPF). Buloxibutid (C21) is a first-in-class orally available small molecule angiotensin II type 2 receptor agonist (ATRAG) recently completing a Phase 2a trial in IPF. Almee™ (an investigational medical device in clinical development) is a digital therapeutic based on cognitive behavioral therapy created to address the psychological impact of living with pulmonary fibrosis. Almee has received Breakthrough Device Designation from the FDA, reflecting its potential to have transformative impact. Using its unique expertise in ATRAG chemistry and biology, Vicore is further fueling its pipeline with several new therapies across additional indications.
The company’s shares (VICO) are listed on Nasdaq Stockholm’s main market. For more information, see www.vicorepharma.com